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Research

A Community Hospital Antimicrobial
Stewardship Program’s Assessment of

Prolonged Infusion
Piperacillin-tazobactam for
Pseudomonas Aeruginosa
Pneumonia
By Lee Nguyen, PharmD, BCPS-AQ ID; Paul Gavaza, PhD; Amy Kang, PharmD;
An Nguyen, Liem Hoang, Nguyen Ta

Abstract
Background: The study aim was to determine and compare the length of hospitalization, mortality, clinical stability, and
time to clinical stability of a standard infusion (SI) and prolonged infusion (PI) piperacillin-tazobactam (TZP) in Pseudomonas
aeruginosa ( PA) pneumonia patients.
Methods: This retrospective study evaluated length of hospitalization, mortality, clinical stability, and time to clinical stability
with either SI-TZP or PI-TZP therapy in hospitalized patients diagnosed with PA pneumonia between January 01, 2008 and
June 30, 2014. Patients were included in the study if they received ≥2 days of TZP, were diagnosed with PA pneumonia, and
had TZP therapy initiated within 3 days of the documented PA infection.
Results: A similar proportion of patients achieved clinical stability between the PI (n=14, 70%) and SI (n=22, 67%)
groups, (p=0.8). There was no statistically significant difference in the average time to clinical stability between the PI
(mean=5.3±3.6) and SI (mean=5.8±6.8) groups, (p=0.77). The total length of stay in the PI group (mean=15.9±9.8) was
shorter than in the SI group (mean=23.9±33) but did not achieve statistical significance, p=0.2. The 14-day all-cause
mortality was similar between the two groups, PI (n=1, 5%) and SI (n=2, 6%).
Conclusion: The use of PI TZP was equally effective as standard therapy. Further research is warranted to confirm these
findings on the clinical benefits of prolonged infusion therapy.

Introduction

M

any hospital antimicrobial stewardship programs are increasingly using piperacillin-tazobactam as
a prolonged infusion (PI).1-7 Similar to
other beta-lactam antibiotics, piperacillin-tazobactam (TZP) is concentration
independent.8 Its antibacterial effects
are optimized when the concentration
of TZP exceeds the minimum inhibi24

tory concentration of the bacterial
organism for at least 50% of the dosing interval.5 Common prolonged infusion TZP utilizes either 3.375 grams or
4 grams infused over 4 hours every 8
hours, whereas standard infusions (SI)
of TZP are infused over 30 minutes
every 6 hours. The desired result common among all hospital stewardship
programs that implement prolonged
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infusions is improved patient outcomes while utilizing less TZP.
Several studies evaluated prolonged infusion of TZP 2-5, 7, 9 and
reported a mix of improved mortality
rates or no difference in treatment outcome.1-3, 7 The majority of the studies
were focused on treating gram-negative infections, with few focusing on
treating Pseudomonas aeruginosa (PA)

infections. Pseudomonas aeruginosa
infections are more difficult to treat
compared to other gram-negative
pneumonias such as E. coli because
of the higher minimum inhibitory
concentrations seen in PA.10 Using
prolonged infusions to maximize TZP
exposure in sicker patients with PA
pneumonia (Acute Physiological and
Chronic Health Evaluation II scores
≥17 ) have been shown to reduce
mortality. Other potential benefits
found were shorter hospital/intensive
care length of stay, fewer days on a
ventilator, and reduced acquisition
cost compared to standard infusions
of TZP.1, 11
Currently, there is limited data on
the use of prolonged infusion TZP in
PA infections.3 There is also limited
information regarding the effects of
prolonged infusion on achieving clinical stability and time to clinical stability in patients with PA pneumonia. The
aim of this study was to evaluate the
clinical effect (e.g., clinical stability and
time to clinical stability) of prolonged
infusion of TZP compared to standard infusion in the treatment of PA
pneumonia. The specific objectives
of the study were to: 1) Determine
and compare the length of hospitalization and mortality of standard
and prolonged infusion of TZP in PA
pneumonia patients, and 2) Determine
and compare clinical stability and time
to clinical stability of standard and
prolonged infusion of TZP in PA pneumonia patients.
Prolonged infusion of TZP was
approved by the Pharmacy and Therapeutics Committee and hospital-wide
conversion was initiated on November
1, 2011. One of the key components
to institutional acceptance of prolonged infusion was garnering the
support from the heads of the different departments that had high utilization of TZP, including internal medicine
and intensivists. Prolonged infusion
therapy is not a new concept, and providing information about which local
and national institutions have adopted
this type of therapy and the rationale
of prolonged infusions diminished
concerns of deploying nontraditional
TZP infusions. Another main compo-

nent of programmatic success was
the hospital-wide use of electronic
infusion pumps. All the infusion pumps
were reprogramed with a default TZP
infusion rate of 13.75 mL/hr, which
equates to a 4 hour infusion. If a
patient required a 30-minute infusion
of TZP, the infusion rate needed to be
entered manually. Lastly, providing
education to the nursing and pharmacy
staff regarding infusion times, dosing adjustments, and compatibilities
issues was necessary to avoid potential medication errors.
Prior to November 1, 2011, all
patients received standard 30-minute
infusions of TZP, and after the implementation date, all patients received
prolonged 4 hour infusions of TZP. The
multiple strengths (2.25, 3.375, and
4.5 grams) and dosing frequencies of
TZP were consolidated into a simpler
format with prolonged infusion . The
institution adopted two major formats
for administering prolonged infusion
of TZP. It is available as 3.375 grams
every 8 hours or 3.375 grams every
12 hours for patients with a creatinine
clearance of less than 20 ml/min.
Hemodialysis patients received 3.375
grams every 12 hours but with a
30-minute infusion. During the evaluation period prior to implementing the
prolonged infusion protocol, the available microbiology records indicated
that the majority of Pseudomonas
aeruginosa had a minimum inhibitory
concentration (MIC) of 8 mg/L. A 4
hour infusion of 3.375 grams of TZP
has a >90% probability of attaining the
target of 50% free drug exceeding the
MIC.12

Methods
The St. Jude Medical Center
Institutional Review Board approved
this retrospective chart-review study.
This study evaluated all patients with
PA pneumonia that were hospitalized
between January 01, 2008 and June
30, 2014. Patients were selected for
inclusion in the study if they received
≥2 days of TZP, were diagnosed with
PA pneumonia based on International
Classification of Diseases, Ninth
Revision, Clinical Modification (ICD9-CM) code of 482.1 , and had TZP

therapy initiated within 3 days of the
documented PA infection. Patients
were excluded from the study if they
had isolated a PA resistance to TZP,
received concomitant effective betalactam therapy for the PA pneumonia,
were diagnosed with cystic fibrosis,
or were on hemodialysis. Pharmacy
utilization records were used in conjunction with ICD-9 codes to identify
which patients had PA pneumonia and
utilization of TZP. If PA pneumonia and
TZP utilization were isolated on multiple occasions during the study period,
only the first episode of infection was
reviewed. Each patient record was
evaluated to determine inclusion or
exclusion from the study.
Medical charts for the included
patients were reviewed for pertinent
demographic, determination of TZP
infusion type, laboratory, microbiology information, and clinical data to
determine clinical stability. Patient
data included age, gender, comorbid
conditions, intensive care unit (ICU)
admission, mechanical ventilation,
length of stay (LOS), onset of infection location, Pseudomonas aeruginosa MICs, and in-hospital mortality.
Mortality was defined as all-cause
mortality of hospitalized patients
expiring within 14 days after starting the antibiotic regimen. Comorbid
conditions evaluated included presence of malignancy, chronic kidney
disease, diabetes mellitus, and chronic
obstructive pulmonary disease. A
Charlson Comorbidity Index (CCI)
score was calculated at the time TZP
was initiated to quantify the number
of comorbid conditions and risk of
mortality.13 Each comorbid condition
was identified through medical charts.
Primary endpoints evaluated were
clinical stability and time to clinical
stability. Clinical stability was defined
as heart rate ≤100 beats/min, systolic
blood pressure ≥90 mm Hg, respiratory rate ≤24/min, oxygen saturation
≥90%, and temperature ≤37.2°C.
Time to clinical stability was defined
as the number of days required for
clinical stability parameters to return
to normal values for more than 24
hours since TZP initiation. Secondary
endpoints evaluated were all-cause in-
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Table 1. Demographic Information of the Patients
Characteristics

PI (n=20)

SI (n=33)

P-value

75 (53-79)

69 (64-79)

0.71

Male, No. (%)

11 (55)

18 (55)

0.97

Female, No. (%)

9 (45)

15 (45)

White

13 (65)

25 (75.8)

Others

7 (35)

8 (24.2)

Home

16 (80)

22 (66.7)

SNF or OSH

4 (20)

11 (33.3)

Diabetes Mellitus

5 (25)

5 (15.2)

0.47

COPD

6 (30)

13 (39.4)

0.49

Cancer

6 (30)

7 (21.2)

0.47

Chronic Kidney Disease

3 (15)

2 (6.1)

*

CCI Score, median (IQR)

5 (3.8-7)

5 (4-6)

0.92

Number of comorbidities, median (IQR)

2 (0.8-4)

1 (1-2)

*

Fluoroquinolones

5 (25)

20 (60.6)

0.02

Aminoglycosides

8 (40)

8 (24.2)

0.23

Onset of infection, ICU

10 (50)

14 (42.4)

0.59

Mechanical ventilation, No. (%)

14 (70)

18 (54.5)

0.26

16.4±10.3

13.7±13.6

0.51

Age (years), median (IQR)
Gender

Ethnicity, No. (%)
0.4

Residence, No. (%)
0.35

Comorbidities, No. (%)

Concomitant antibiotics, No. (%)

Days on mechanical ventilation, mean ±SD
CrCl (ml/min), No. (%)
CrCl >50

12 (60)

27 (81.8)

0.08

CrCl 21-50

5 (25)

4 (12.1)

0.27

CrCl ≤20

3 (15)

2 (6.1)

*

8.4 ±4.3

8.3 ±7.9

0.99

2.25 grams every 6 hours

0 (0)

5 (15.2)

*

3.375 grams every 6 hours

0 (0)

19 (57.6)

*

3.375 grams every 8 hours

16 (80)

9 (27.3)

0.0002

3.375 grams every 12 hours

3 (15)

0 (0)

*

4.5 grams every 8 hours

1 (5)

0 (0)

*

9.8

11.9

Duration of therapy (days), mean ±SD
Treatment regimens, No. (%)

Average TZP gram per patient per day
*

Indicates that data cells in one or more cells is too small (<5) to allow the computation of P-value
TZP: piperacillin-tazobactam, PI: prolonged infusion, SI: standard infusion, SNF: skilled nursing facilities,
OSH: outside hospital, COPD: chronic obstructive pulmonary disease, CCI: Charlson Comorbidity Index,
IQR: interquartile range, CrCl: creatinine clearance estimated by Cockcroft-Gault
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Table 2. Primary Outcomes of the Patients
Achieved clinical stability, No. (%)
Time to clinical stability (days), mean ±SD

PI (n=20)

SI (n=33)

P-value

14 (70)

22 (66.7)

0.80+

5.3 ±3.6

5.8 ±6.8

0.77+

Hospital LOS (days), No. (%)
Post-culture, mean ±SD

11.5 ±6.3

19.8 ±33.0

0.17+

Total, mean ±SD

15.9 ±9.8

23.9 ±33.0

0.20+

1 (5)

2 (6.1)

*

Mortality, 14-day (all-cause), No. (%)

Indicates that data cells in one or more cells is too small (<5) to allow the computation of P-value, +independent t-test

*

LOS: length of stay

hospital 14-day mortality and LOS.

Data Analysis
Descriptive statistics were computed for all study variables that
were measured on an interval or ratio
scale. Discrete data were presented
as frequencies and percentages. The
independent student t-test was used
to compare mean CCI score differences, LOS, number of patients who
achieved clinical stability, and the
average time to clinical stability by
the type of infusion received. Either
Pearson’s chi-square test or Fisher’s
test was used to measure the association between dichotomous variables.
All tests were two-tailed and a P-value
of <0.05 was considered significant.
Statistical analyses were carried out
with SPSS version 20.0 (Chicago, IL,
USA) and GraphPad Prism version 6.0
(San Diego, CA, USA).

Results
During the study period, 122
patients were identified as having PA
pneumonia. Fifty-three patients with
a median age of 72 (SD±15.1) years
met the inclusion criteria and were
included in the study. Twenty patients
received standard infusions of TZP
and 33 patients received prolonged
infusions of TZP. The majority of the
patients were men (55%) and Caucasian (72%) who resided at home
(72%) prior to hospitalization. Baseline
characteristics are listed in Table 1.
The demographics of the two
groups did not differ, with the exception of concomitant fluoroquinolone
utilization (PI: 25% vs SI: 61%,

p=0.02), and type of TZP infusion.
Table 1 lists different treatment
regimens used for the Pseudomonas
pneumonias. The most common regimen of the PI group was 3.375 grams
every 8 hours (n=16, 80%) with 3.375
grams every 6 hours (n=19, 58%) as
the most common regimen in the
standard 30-minute infusion group.
The average amount of TZP utilized
was lower in the PI group, (9.8 grams
vs 11.9 grams). There was no difference in duration of therapy (mean days
±SD) between the two groups (PI:
8.4±4.3 vs SI: 8.3±7.9, p=0.99).
There was no statistically significant difference in the proportion of
patients in the prolonged infusion
group (n=14, 70%) and the short infusion group (n=22, 67%) who achieved
clinical stability (p=0.8; Table 2). The PI
group (n=2, 10%) had a lower number
of patients who were clinically stable
at onset of TZP therapy compared
to the SI group (n=10, 30%). When
excluding the number of patients that
were clinically stable at the onset of
TZP therapy, the PI group (n=12, 60%)
had higher rates of achieving clinical
stability compared to the SI group
(n=12, 36%) but did not reach significance, p=0.09. There was no statistically significant difference in the mean
time to clinical stability days between
the PI group (mean = 5.3±3.6) and the
SI group (mean = 5.8±6.8, p=0.77).
The total LOS (mean days ±SD) in
the PI group (15.9 ±9.8) was shorter
than the SI group (23.9 ±33) but did
not achieve statistical significance,
p=0.2. The 14-day all-cause mortality
was similar between patients in the PI

group (n=1, 5%) and those in the short
infusion group (n=2, 6%).
The distribution of MICs can be
seen in Table 3. The most common
MIC in each group was 8 mg/L (PI:
79% vs SI: 48%). The SI group had
a larger proportion of patients with
MICs >8 mg/L, (PI: 16% vs SI: 52%,
p=0.03). Nine patients had susceptibilities performed using the Kirby-Bauer
Disk Diffusion test and no MICs were
available.

Discussion
This study evaluated the clinical
outcomes associated with prolonged
infusion piperacillin-tazobactam and
standard infusion therapy for the
treatment of Pseudomonas aeruginosa pneumonia. Study results show
that patients who received prolonged
infusions of TZP achieved similar rates
of clinical stability to that of standard
infusion, 70% vs 67%. Additionally,
the time to clinical stability in the
prolonged infusion group was similar
to that of the standard infusion group,
5.3 days vs 5.8 days. This suggests
that a 4 hour TZP infusion does not
delay the time to clinical stability or
limit the patients’ ability to achieve
clinical stability. The results of our
study are similar to others in which
the use of prolonged infusion of TZP
was equally effective as standard
therapy.4, 5, 9 To our knowledge, this is
the first study that evaluated prolonged infusion piperacillin-tazobactam
for the treatment of Pseudomonas
aeruginosa pneumonia and associated
effects on clinical stability and time to
clinical stability.
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Table 3. Microbiology
Minimum Inhibitory
Concentration (mg/L)

PI
(N, %)

SI
(N, %)

4

1 (5)

0

8

15 (79)

12 (48)

16

0

2 (8)

32

0

5 (20)

64

3 (16)

6 (24)

Nine patients did not have minimum inhibitory concentrations (PI: n=1, SI: n=8);
Kirby-Bauer Disk Diffusion tests were used to determine susceptibility.

Similar mortality rates (5% vs 6%)
and length of stay (16 days vs 24 days)
were found between the two groups
in this study, thus further supporting
that prolonged infusion of TZP is as
effective as standard infusion therapy
for the treatment of Pseudomonas
pneumonia. These results differ from
those by Lodise et al , who showed
mortality benefit in patients with elevated Acute Physiology and Chronic
Health Evaluation and PA infections,3
probably due to our smaller sample
size (n=53 vs N=103 PA pneumonias),
older patient population, and the fact
that our evaluation was limited to PA
pneumonia infections.
The main difference between
the two groups was the amount of
TZP utilized and the frequency of the
infusions. On average the prolonged
infusion group (9.8 grams) used less
TZP than the standard infusion group
(11.9 grams). Seventy-three percent
of the SI group (n=24) received TZP
doses every 6 hours, but the majority
of the PI group (n=17, 85%) received
TZP doses every 8 hours.
Our study has several limitations.
First, several variables that may
influence patient outcomes were not
included on patient charts that were
utilized for this study. These variables
include other comorbid conditions or
co-infections that may prevent clinical
stability or delay time to clinical stability, such as cardiovascular disease.
Consequently, the Charlson Comorbidity Index was used to capture
the presence of 17 comorbid conditions,13 but the conceded limitation is
a potential incomplete capture of all
possible comorbidity information. A
28

second limitation is the small sample
size. The small sample size is a consequence of looking at Pseudomonas
pneumonia in a community hospital
with carbapenems as the preferred
agent, thus limiting the utilization of
TZP. The antimicrobial stewardship
program was formalized in the middle
of 2011 and the majority of patients
prior to 2011 received a carbapenem
empirically for the treatment of Pseudomonas infections. Lastly, there is a
discrepancy in the distribution of the
Pseudomonas aeruginosa minimum
inhibitory concentrations for TZP.
In 2012, the Clinical and Laboratory
Standards Institute (CLSI) lowered the
susceptibility breakpoint from ≤64/4
mcg/mL to ≤16/4 mcg/mL. The lowered breakpoint introduced a potential
selection bias with fewer patients in
the prolonged infusion group having
MICs higher than 8 mcg/mL.
As more institutions are considering the adoption of prolonged infusion
TZP, the immediate consideration
is efficacy compared to standard
therapy. Current clinical evidence
suggests that prolonged infusion of
TZP has similar efficacy as standard
infusions.1-5, 7, 9, 11 Other considerations
are the financial costs and impact on
patient care. Using one less dose of
TZP makes the process financially
appealing. Standard amounts of
TZP consumed ranges from 13.5-18
grams/day . Prolonged infusion of TZP
would reduce the daily consumption
to as little as 10.125 grams/day. Prolonged infusions may impact patient
care on multiple levels. Piperacillintazobactam is incompatible with a
various medications such as amioda-
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rone, azithromycin, and pantoprazole.14
The 4 hour infusion of TZP will limit
other medications from being infused
or would require a second intravenous
access line. Prolonged infusion of
TZP is also not ideal for patients in
the emergency department. Having
patients occupy a bed for 4 hours
unnecessarily would be counterproductive in a fast-paced environment.
Lastly, prolonged infusion of TZP therapy lasts 12 hours a day and will limit
the activity of ambulatory patients.

Conclusion
As antimicrobial stewardship
programs implement new ideas into
practice, it is necessary to review and
evaluate them to ensure patient safety.
Currently, there is limited data on the
benefit of prolonged infusion in Pseudomonas infections, with the exception of reduced antibiotic utilization.
The study shows that patients receiving prolonged infusion had similar
rates of achieving clinical stability and
took similar amounts of time to clinical
stability than those receiving standard
infusion. The use of prolonged infusion of TZP was found to be equally
effective as standard therapy. Further
research using a larger sample is warranted to confirm these findings on the
clinical benefits of prolonged infusion
therapy.
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